{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:45:02Z","timestamp":1792129502868,"version":"4.4.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1053\/j.seminhematol.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:36:33Z","timestamp":1780500993000},"page":"91-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis"],"prefix":"10.1053","volume":"63","author":[{"given":"Katherine J.","family":"Feder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2026.06.003_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100706","article-title":"Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map","volume":"42","author":"Shallis","year":"2020","journal-title":"Blood Rev"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.06.003_bib0002","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.3390\/cancers17193142","article-title":"Advances in the diagnosis and treatment of myeloproliferative neoplasms (MPNs)","volume":"17","author":"Ma","year":"2025","journal-title":"Cancers"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0003","series-title":"StatPearls","article-title":"Myeloproliferative neoplasms","author":"Thapa","year":"2026"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.003_bib0004","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/joim.13019","article-title":"Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden","volume":"287","author":"Hultcrantz","year":"2020","journal-title":"J Intern Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.003_bib0005","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States","volume":"63","author":"Verstovsek","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.06.003_bib0006","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3390\/cancers12071810","article-title":"Aetiology of myeloproliferative neoplasms","volume":"12","author":"McMullin","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.003_bib0007","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3892\/ol.2016.4192","article-title":"A case of myeloproliferative neoplasm with a normal complete blood cell count: a novel problem of the JAK2 era","volume":"11","author":"Ye","year":"2016","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.003_bib0008","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bjh.19557","article-title":"Myeloproliferative neoplasms in the adolescent and young adult population: a comprehensive review of the literature","volume":"205","author":"Goulart","year":"2024","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0009","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/pbc.21462","article-title":"Registration and classification of adolescent and young adult cancer cases","volume":"50","author":"Pollock","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0010","series-title":"NCCN clinical practice guidelines in oncology: myeloproliferative neoplasms","year":"2026"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.003_bib0011","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.06.003_bib0012","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0013","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.06.003_bib0014","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2023020232","article-title":"Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL","volume":"143","author":"Gerds","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.06.003_bib0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.06.003_bib0016","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737159.2025.2573466","article-title":"Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models","volume":"25","author":"Loscocco","year":"2025","journal-title":"Expert Rev Mol Diagn"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0017","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1007\/s00277-025-06361-7","article-title":"Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis","volume":"104","author":"Morath","year":"2025","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.06.003_bib0018","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1055\/a-2239-9265","article-title":"DNMT3A\/TET2\/ASXL1 Mutations are an age-independent thrombotic risk factor in Polycythemia Vera patients: an observational study","volume":"124","author":"Segura-D\u00edaz","year":"2024","journal-title":"Thromb Haemost"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.003_bib0019","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s11864-024-01255-8","article-title":"Myeloproliferative neoplasms and cardiovascular Disease: a review","volume":"25","author":"Leiva","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.003_bib0020","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41375-023-02114-5","article-title":"Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification","volume":"38","author":"Pasquer","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.003_bib0021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.2024025459","article-title":"Current myeloproliferative neoplasm scoring systems for clinical practice","volume":"145","author":"Pasquer","year":"2025","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.06.003_bib0022","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2023021503","article-title":"Moving toward disease modification in polycythemia vera","volume":"142","author":"Bewersdorf","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.06.003_bib0023","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia Vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.003_bib0024","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70137","article-title":"Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea\/best available therapy (PROUD-PV\/CONTINUATION-PV)","volume":"9","author":"Kiladjian","year":"2025","journal-title":"HemaSphere"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0026","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/bloodadvances.2025018011","article-title":"Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways","volume":"10","author":"Barbui","year":"2026","journal-title":"Blood Adv"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.06.003_bib0027","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood.2025032534","article-title":"Introduction to a review series on the new wave of targeted therapeutics for MPNs","volume":"147","author":"Gotlib","year":"2026","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.003_bib0028","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.003_bib0029","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in Polycythemia Vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-2007-996124","article-title":"European Collaboration on low-dose aspirin in Polycythemia Vera (ECLAP): a randomized trial","volume":"23","author":"Landolfi","year":"1997","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.003_bib0031","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.06.003_bib0032","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-018-0161-9","article-title":"Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0033","article-title":"Evaluation of therapeutic strategies to reduce the number of thrombotic events in patients with polycythemia vera and essential thrombocythemia","volume":"10","author":"Tremblay","year":"2020","journal-title":"Front Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.06.003_bib0034","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.06.003_bib0035","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2796.1993.tb01019.x","article-title":"Polycythaemia vera and cerebral blood flow: a preliminary study with transcranial Doppler","volume":"234","author":"Fiermonte","year":"1993","journal-title":"J Intern Med"},{"issue":"8030","key":"10.1053\/j.seminhematol.2026.06.003_bib0036","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(77)90179-9","article-title":"Cerebral blood-flow in polycythaemia","volume":"2","author":"Thomas","year":"1977","journal-title":"Lancet"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.06.003_bib0037","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.003_bib0038","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in Polycythemia Vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"8102","key":"10.1053\/j.seminhematol.2026.06.003_bib0039","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia","volume":"2","author":"Pearson","year":"1978","journal-title":"Lancet"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.06.003_bib0040","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1182\/blood-2003-04-1033","article-title":"Elevated hematocrit, risk of thrombosis, and polycythemia vera","volume":"101","author":"Prchal","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0041","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jtha.2023.01.027","article-title":"JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions","volume":"21","author":"Beckman","year":"2023","journal-title":"J Thromb Haemost JTH"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0042","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2017.26","article-title":"JAK2-V617F activates \u03b21-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1","volume":"31","author":"Gupta","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.06.003_bib0043","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/10428194.2025.2503458","article-title":"Validation of the triple a model (age, absolute neutrophil count, absolute lymphocyte count) for the prediction of survival and thrombosis in 1000 patients with polycythemia vera","volume":"66","author":"Lekovic","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.003_bib0044","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-022-00625-5","article-title":"Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera","volume":"12","author":"Carobbio","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.003_bib0045","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41375-025-02836-8","article-title":"Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms","volume":"40","author":"Guy","year":"2026","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.003_bib0046","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/s41375-025-02681-9","article-title":"QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms","volume":"39","author":"Duminuco","year":"2025","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0047","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/VHRM.S429995","article-title":"Diagnosis and management of cardiovascular risk in patients with Polycythemia Vera","volume":"19","author":"Benevolo","year":"2023","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.003_bib0048","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.19154","article-title":"Quantitative interpretation of bone marrow biopsies in MPN-what\u2019s the point in a molecular age?","volume":"203","author":"Ryou","year":"2023","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.003_bib0049","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.06.003_bib0050","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood-2021-153221","article-title":"Iron deficiency in polycythemia Vera increases HIF activity and transcription of prothrombotic genes","volume":"138","author":"Song","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.06.003_bib0051","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/s41375-025-02623-5","article-title":"Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM)","volume":"39","author":"Heidel","year":"2025","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0052","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9124821","article-title":"The essential thrombocythemia, thrombotic risk stratification, and cardiovascular risk factors","volume":"2020","author":"Mancuso","year":"2020","journal-title":"Adv Hematol"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0053","doi-asserted-by":"crossref","unstructured":"Tefferi A, Pardanani A. Essential thrombocythemia. Solomon CG, ed. N Engl J Med 2019;381(22):2135-44. doi:10.1056\/NEJMcp1816082.","DOI":"10.1056\/NEJMcp1816082"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.06.003_bib0054","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International prognostic Score of thrombosis in World Health Organization\u2013essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0055","doi-asserted-by":"crossref","unstructured":"Tefferi A, Pardanani A. Essential thrombocythemia. Solomon CG, ed. N Engl J Med 2019;381(23):2135-44. doi:10.1056\/NEJMcp1816082.","DOI":"10.1056\/NEJMcp1816082"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.003_bib0056","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jama.2024.25349","article-title":"Essential thrombocythemia: a review","volume":"333","author":"Tefferi","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.003_bib0057","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9464","key":"10.1053\/j.seminhematol.2026.06.003_bib0058","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"10.1053\/j.seminhematol.2026.06.003_bib0059","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.06.003_bib0060","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.003_bib0061","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised International Prognostic Score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.06.003_bib0062","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization\u2013defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.003_bib0063","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0064","unstructured":"Hydrea (hydroxyurea) capsules [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2016."},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0065","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7753857","article-title":"Mechanisms of hydroxyurea-induced cellular senescence: an oxidative stress connection?","volume":"2021","author":"Kapor","year":"2021","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.003_bib0066","first-page":"1","article-title":"Mechanism of action of hydroxyurea","volume":"19","author":"Yarbro","year":"1992","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.003_bib0067","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jama.2024.20377","article-title":"Diagnosis and treatment of Polycythemia Vera: a review","volume":"333","author":"Tremblay","year":"2025","journal-title":"JAMA"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.06.003_bib0068","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0069","unstructured":"UpToDate. Hydroxyurea (Hydroxycarbamide): drug information. Accessed March 31 2026. https:\/\/www.uptodate.com\/contents\/hydroxyurea-hydroxycarbamide-drug-information?search=hydroxyurea&source=panel_search_result&selectedTitle=1\u223c113&usage_type=panel&kp_tab=drug_general&display_rank=1#F57216063."},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0070","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13043","article-title":"Nonmelanoma skin cancer associated with hydroxyurea treatment: overview of the literature and our own experience","volume":"32","author":"Cantisani","year":"2019","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.003_bib0071","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0072","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2016.06.013","article-title":"Second line therapies in polycythemia vera: what is the optimal strategy after hydroxyurea failure?","volume":"105","author":"Nazha","year":"2016","journal-title":"Crit Rev Oncol Hemato"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.003_bib0073","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.06.003_bib0074","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3390\/cancers17111834","article-title":"Current advances in the diagnosis and treatment of major myeloproliferative neoplasms","volume":"17","author":"Wang","year":"2025","journal-title":"Cancers"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-016-0031-8","article-title":"Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review","volume":"5","author":"Parasuraman","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.06.003_bib0076","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0077","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjh.13886","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera","volume":"172","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.06.003_bib0078","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.06.003_bib0079","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0080","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/bloodadvances.2022008259","article-title":"Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea","volume":"7","author":"Wang","year":"2023","journal-title":"Blood Adv"},{"issue":"29","key":"10.1053\/j.seminhematol.2026.06.003_bib0081","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.003_bib0082","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin Immunopathol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.003_bib0083","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V76.4.664.664","article-title":"A new treatment for polycythemia vera: recombinant interferon alfa","volume":"76","author":"Silver","year":"1990","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.003_bib0084","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/hematology.2024000577","article-title":"Pegylated interferon: the who, why, and how","volume":"2024","author":"Kiladjian","year":"2024","journal-title":"Hematology"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0085","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241229588","article-title":"Interferons in the treatment of myeloproliferative neoplasms","volume":"15","author":"Vachhani","year":"2024","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.003_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00343-4","article-title":"Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials","volume":"9","author":"Mazza","year":"2022","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.06.003_bib0087","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.06.003_bib0088","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2023-173127","article-title":"Final analysis of the Daliah trial: a randomized Phase III trial of interferon-\u03b1 versus hydroxyurea in patients with MPN","volume":"142","author":"Knudsen","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.06.003_bib0089","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1182\/blood-2018-99-118584","article-title":"Long-term efficacy and safety of Ropeginterferon Alfa-2b in patients with Polycythemia Vera \u2014 Final Phase I\/II Peginvera study results","volume":"132","author":"Gisslinger","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0090","unstructured":"BESREMi (ropeginterferon alfa-2b-njft) injection [package insert]. Burlington, MA: PharmaEssentia Corporation; 2021."},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0091","unstructured":"Novel Drug Approvals for 2021. US Food & Drug Administration. Accessed March 31, 2026. https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2021."},{"issue":"9","key":"10.1053\/j.seminhematol.2026.06.003_bib0092","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","article-title":"Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival","volume":"35","author":"Abu-Zeinah","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.003_bib0093","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/17474086.2023.2198698","article-title":"Polycythemia vera: aspects of its current diagnosis and initial treatment","volume":"16","author":"Silver","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.06.003_bib0094","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood.2023020729","article-title":"How I treat myeloproliferative neoplasms in pregnancy","volume":"143","author":"Robinson","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.003_bib0095","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.06.003_bib0096","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200335","article-title":"Ropeginterferon versus Standard therapy for low-risk patients with Polycythemia Vera","volume":"2","author":"Barbui","year":"2023","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.06.003_bib0097","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1159\/000544818","article-title":"ECLIPSE-PV: a randomized, multicenter study to assess efficacy, safety, and tolerability of two dosing regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera","volume":"148","author":"Mascarenhas","year":"2025","journal-title":"Acta Haematol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.06.003_bib0098","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1182\/blood-2024-199337","article-title":"Paradigm-PV: a global, randomized, multicenter, two-arm phase IV study to assess the efficacy and safety of Ropeginterferon Alfa-2b in low- and high-risk patients with Polycythemia Vera","volume":"144","author":"Yacoub","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.06.003_bib0099","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.1182\/blood-2025-7338","article-title":"Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: practice patterns, tolerance, and outcomes","volume":"146","author":"Feder","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0100","unstructured":"UpToDate. Ropeginterferon Alfa-2b: drug information. Accessed March 31 2026. https:\/\/www.uptodate.com\/contents\/ropeginterferon-alfa-2b-drug-information?search=ropeginterferon&source=panel_search_result&selectedTitle=1\u223c7&usage_type=panel&kp_tab=drug_general&display_rank=1."},{"issue":"24","key":"10.1053\/j.seminhematol.2026.06.003_bib0101","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0102","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/CLEP.S162688","article-title":"Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark","volume":"11","author":"Brochmann","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.06.003_bib0103","doi-asserted-by":"crossref","first-page":"8301","DOI":"10.1002\/cam4.3380","article-title":"Depressive symptoms and myeloproliferative neoplasms: understanding the confounding factor in a complex condition","volume":"9","author":"Padrnos","year":"2020","journal-title":"Cancer Med"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.06.003_bib0104","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1182\/blood-2024-211986","article-title":"Disparities in depression: the role of race and gender in patients with myeloproliferative neoplasms, an analysis of the national inpatient sample (NIS) (2016-2020)","volume":"144","author":"Sangam","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0105","unstructured":"Incyte Corporation FDL. Ruxolitinib. Published online 2011. Accessed March 31 2026."},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.003_bib0106","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus Standard therapy for the treatment of Polycythemia Vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.003_bib0107","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0108","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2017.01.032","article-title":"Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy","volume":"56","author":"Verstovsek","year":"2017","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0109","unstructured":"National Library of Medicine. The Ruxo-BEAT trial in patients with high-risk polycythemia vera or high-risk essential thrombocythemia (Ruxo-BEAT). Accessed March 30, 2026. https:\/\/clinicaltrials.gov\/study\/NCT02577926#participation-criteria."},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.06.003_bib0110","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood-2023-173225","article-title":"Firstline treatment with Ruxolitinib versus best available therapy in patients with Polycythemia Vera: pre-specified interim analysis of the randomized phase 2b Ruxobeat clinical trial of the German Study Group for myeloproliferative neoplasms (GSG-MPN)","volume":"142","author":"Koschmieder","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.06.003_bib0111","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1182\/blood-2024-194126","article-title":"Trial-in-progress: a phase 2 study of Ruxolitinib in low-risk essential thrombocythemia and polycythemia vera patients with high symptom burden","volume":"144","author":"How","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.003_bib0112","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1007\/s00277-024-05735-7","article-title":"Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice","volume":"103","author":"Chojecki","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0113","unstructured":"UpToDate. Ruxolitinib (Systemic): drug information. Access date March 31 2026 https:\/\/www.uptodate.com\/contents\/ruxolitinib-systemic-drug-information?search=ruxolitinib&source=panel_search_result&selectedTitle=1\u223c77&usage_type=panel&showDrugLabel=true&display_rank=1."},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.003_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.09.035","article-title":"Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment","volume":"70","author":"Tong","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.003_bib0115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2013.235","article-title":"Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis","volume":"28","author":"Caocci","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.06.003_bib0116","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood-2018-01-791491","article-title":"The role of JAK2 inhibitors in MPNs 7 years after approval","volume":"131","author":"Passamonti","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.003_bib0117","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ajh.27418","article-title":"Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: the ARES trial","volume":"99","author":"Rocca","year":"2024","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.06.003_bib0118","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.003_bib0119","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.003_bib0120","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.003_bib0121","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11239-015-1218-2","article-title":"Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis","volume":"40","author":"Samuelson","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"34","key":"10.1053\/j.seminhematol.2026.06.003_bib0122","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2018.78.8414","article-title":"Hydroxycarbamide plus Aspirin versus Aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features","volume":"36","author":"Godfrey","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.003_bib0123","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000521","article-title":"Low-risk essential thrombocythemia: a comprehensive review","volume":"5","author":"Robinson","year":"2021","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.06.003_bib0124","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2024-198336","article-title":"Prognostic value of response to first-line hydroxyurea according to Ipset stratification in essential thrombocythemia","volume":"144","author":"Santaliestra","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.06.003_bib0125","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.003_bib0126","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jth.12850","article-title":"Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms","volume":"13","author":"Espasandin","year":"2015","journal-title":"J Thromb Haemost JTH"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0127","unstructured":"Agrylin (anagrelide hydrochloride) [package insert]. Eatontown, NJ: Roberts Laboratories Inc; 1997."},{"issue":"27","key":"10.1053\/j.seminhematol.2026.06.003_bib0128","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2217\/fon-2022-0596","article-title":"SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia","volume":"18","author":"Verstovsek","year":"2022","journal-title":"Future Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.06.003_bib0129","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/S2352-3026(25)00264-9","article-title":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study","volume":"12","author":"Mesa","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2026.06.003_bib0130","article-title":"Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)","volume":"61","author":"Reeves","year":"2026","journal-title":"Lancet Reg Health Am"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.06.003_bib0131","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00277-024-05665-4","article-title":"ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options","volume":"103","author":"Kiladjian","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.003_bib0132","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11899-024-00749-4","article-title":"Mutant calreticulin in MPN: mechanistic insights and therapeutic implications","volume":"20","author":"Faiz","year":"2025","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.003_bib0133","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41375-018-0295-6","article-title":"JAK2V617F but not CALR mutations confer increased molecular responses to interferon-\u03b1 via JAK1\/STAT1 activation","volume":"33","author":"Czech","year":"2019","journal-title":"Leukemia"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.06.003_bib0134","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.003_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100167","article-title":"Real-world analysis of polycythemia vera treatment reveals nonadherence to NCCN guidelines in a large proportion of patients","volume":"2","author":"Abu-Zeinah","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.003_bib0136","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann Hematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:58:22Z","timestamp":1792126702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0037196326000612"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.06.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}